Nexstim
Medical Devices, 1959 Parker Ct, Helsinki, Georgia, 30087, United States, 11-50 Employees
Phone Number: +12*********
Who is NEXSTIM
Nexstim is a Finnish, globally operating medical technology company. Founded in 2000 in Helsinki, Finland, Nexstim is committed to improving the quality of life of patients with significa...
Read More
-
Headquarters: 1959 Parker Ct, Helsinki, Georgia, 30087, United States
-
Date Founded: 2000
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Medical Devices
SIC Code: 5047
|
NAICS Code: 999990 |
Show More
Nexstim Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Nexstim
Answer: Nexstim's headquarters are located at 1959 Parker Ct, Helsinki, Georgia, 30087, United States
Answer: Nexstim's phone number is +12*********
Answer: Nexstim's official website is https://nexstim.com
Answer: Nexstim's revenue is $1 Million to $5 Million
Answer: Nexstim's SIC: 5047
Answer: Nexstim's NAICS: 999990
Answer: Nexstim has 11-50 employees
Answer: Nexstim is in Medical Devices
Answer: Nexstim contact info: Phone number: +12********* Website: https://nexstim.com
Answer: Nexstim is a Finnish, globally operating medical technology company. Founded in 2000 in Helsinki, Finland, Nexstim is committed to improving the quality of life of patients with significant unmet clinical needs. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. SmartFocus technology is used in Nexstims proprietary Navigated Brain Therapy (NBT) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT system is CE marked for the treatment of major depression and chronic neuropathic pain. In addition, Nexstim is commercializing its SmartFocus based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on Nasdaq First North Growth Market Finland.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month